

DAFTAR PUSTAKA

- Agu, P. C., Afiukwa, C. A., Orji, O. U., Ezech, E. M., Ofoke, I. H., Ogbu, C. O., Ugwuja, E. I., & Aja, P. M. (2023). Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. *Scientific Reports*, 13(1), 13398. <https://doi.org/10.1038/s41598-023-40160-2>
- Alos, H. C., Billones, J. B., Castillo, A. L., & Vasquez, R. D. (2022). Alpinumisoflavone against cancer pro-angiogenic targets: in silico, in vitro, and in ovo evaluation. *DARU Journal of Pharmaceutical Sciences*, 30(2), 273–288. <https://doi.org/10.1007/s40199-022-00445-9>
- Aulifa, D. L., Amirah, S. R., Rahayu, D., Megantara, S., & Muchtaridi, M. (2024). Pharmacophore modeling and binding affinity of secondary metabolites from *Angelica keiskei* to HMG co-A reductase. *Molecules*, 29(13), 2983. [10.3390/molecules29132983](https://doi.org/10.3390/molecules29132983)
- Baby, B., Antony, P., & Vijayan, R. (2018). Interactions of quercetin with receptor tyrosine kinases associated with human lung carcinoma. *Natural Product Research*, 32(24), 2928–2931. <https://doi.org/10.1080/14786419.2017.1385015>
- Chen, J., Zhao, L., Xu, M.-F., Huang, D., Sun, X.-L., Zhang, Y.-X., Li, H.-M., & Wu, C.-Z. (2024). Novel isobavachalcone derivatives induce apoptosis and necroptosis in human non-small cell lung cancer H1975 cells. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 39(1), 2292006. <https://doi.org/10.1080/14756366.2023.2292006>
- Cheng, W., Liu, D., Guo, M., Li, H., & Wang, Q. (2022). Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR–PI3K–AKT signaling. *Drug Development Research*, 83(5), 1138–1151. <https://doi.org/10.1002/ddr.21938>
- Chipón, C., Riffo, P., Ojeda, L., Salas, M., Burgos, R. A., Ehrenfeld, P., López-Muñoz, R., & Zambrano, A. (2024). Impact of nordihydroguaiaretic acid on proliferation, energy metabolism, and chemosensitization in non-small-cell lung cancer (NSCLC) cell lines. *International Journal of Molecular Sciences*, 25(21), 11601. [10.3390/ijms252111601](https://doi.org/10.3390/ijms252111601)
- Dandagvhal, K., & Chatpalliwar, V. (2022). in silico characterization, ADMET prediction and molecular docking studies of few 2/3 carboxylate-4/5/6-monosubstituted indole derivatives as potential GSK-3 β inhibitors. *International Journal of Health Sciences*, 6(S3), 12193–12212. <https://doi.org/10.53730/ijhs.v6nS3.9119>
- Daoui, O., Elkhatabi, S., Chtita, S., Elkhlabi, R., Zgou, H., & Benjelloun, A. T. (2021). QSAR, molecular docking and ADMET properties in silico studies

of novel 4, 5, 6, 7-tetrahydrobenzo [D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase. *Heliyon*, 7(7). [https://www.cell.com/heliyon/fulltext/S2405-8440\(21\)01566-8](https://www.cell.com/heliyon/fulltext/S2405-8440(21)01566-8)

DeMarini, D. M. (2021). *The role of genotoxicity in carcinogenesis*. [Ebook]. <https://europepmc.org/article/nbk/nbk570347>

Esteban-Villarrubia, J., Soto-Castillo, J. J., Pozas, J., San Román-Gil, M., Orejana-Martín, I., Torres-Jiménez, J., Carrato, A., Alonso-Gordoa, T., & Molina-Cerrillo, J. (2020). Tyrosine kinase receptors in oncology. *International Journal of Molecular Sciences*, 21(22), 8529. 10.3390/ijms21228529

Friedlaender, A., Perol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024). Oncogenic alterations in advanced NSCLC: a molecular super-highway. *Biomarker Research*, 12(1), 24. <https://doi.org/10.1186/s40364-024-00566-0>. 10.1186/s40364-024-00566-0

Gioia, D., Bertazzo, M., Recanatini, M., Masetti, M., & Cavalli, A. (2017). Dynamic docking: a paradigm shift in computational drug discovery. *Molecules*, 22(11), 2029. 10.3390/molecules22112029

Graedler, U & Lammens, A. (2022, August 25). 8AU5: C-MET F1200I Mutant in complex with tepotinib. RCSB PDB. <https://www.rcsb.org/structure/8AU5>

Hadni, H., & Elhallaouia, M. (2022). In silico design of EGFR L858R/T790M/C797S inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations. *Heliyon*, 8(11). [https://www.cell.com/heliyon/fulltext/S2405-8440\(22\)02825-0](https://www.cell.com/heliyon/fulltext/S2405-8440(22)02825-0)

Jaghooori, M. M., Bleijlevens, B., & Olabarriaga, S. D. (2016). 1001 Ways to run AutoDock Vina for virtual screening. *Journal of Computer-Aided Molecular Design*, 30(3), 237–249. <https://doi.org/10.1007/s10822-016-9900-9>. 10.1007/s10822-016-9900-9

Jeon, J.-S., Kwon, S., Ban, K., Kwon Hong, Y.-, Ahn, C., Sung, J.-S., & Choi, I. (2019). Regulation of the intracellular ROS level is critical for the antiproliferative effect of quercetin in the hepatocellular carcinoma cell line hepG2. *Nutrition and Cancer*, 71(5), 861–869. <https://doi.org/10.1080/01635581.2018.1559929>

Jiang, Z., Gu, Z., Yu, X., Cheng, T., & Liu, B. (2024). Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. *Frontiers in Oncology*, 14, 1447678. 10.3389/fonc.2024.1447678

Kashima, K., Kawauchi, H., Tanimura, H., Tachibana, Y., Chiba, T., Torizawa, T., & Sakamoto, H. (2020, Januari 1). 6LUD: crystal structure of

EGFR(L858R/T790M/C797S) in complex with osimertinib. RCSB PDB.
<https://www.rcsb.org/structure/6LUD>

- Koulouris, A., Tsagkaris, C., Corriero, A. C., Metro, G., & Mountzios, G. (2022). Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. *Cancers*, 14(14), 3337. 10.3390/cancers14143337
- Kumar, R., Goel, H., Solanki, R., Rawat, L., Tabasum, S., Tanwar, P., Pal, S., & Sabarwal, A. (2024). Recent developments in receptor tyrosine kinase inhibitors: a promising mainstay in targeted cancer therapy. *Medicine in Drug Discovery*, 23, 100195. 10.1016/j.medidd.2024.100195
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*, 23, 3-25. [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1)
- Lv, H.-W., Wang, Q.-L., Luo, M., Zhu, M.-D., Liang, H.-M., Li, W.-J., Cai, H., Zhou, Z.-B., Wang, H., Tong, S.-Q., & Li, X.-N. (2023). Phytochemistry and pharmacology of natural prenylated flavonoids. *Archives of Pharmacol Research*, 46(4), 207-272. <https://doi.org/10.1007/s12272-023-01443-4>
- Macedo, T., Paiva-Martins, F., Valentão, P., & Pereira, D. M. (2024). In silico and in vitro chemometrics, cell toxicity and permeability of naringenin 8-sulphonate and derivatives. *Frontiers in Pharmacology*, 15, 1398389. <https://doi.org/10.3389/fphar.2024.1398389>
- Mardianingrum, R., Lestary, M. S. R., Aji, N., & Ruswanto, R. (2023). Potential of prenylated flavonoid derivatives from jackfruit roots (*Artocarpus heterophyllus* Lam.) as liver anticancer candidates: In silico study. *Jurnal Kimia Sains dan Aplikasi*, 26(2), 57-63. <https://doi.org/10.14710/jksa.26.2.57-63>
- Mirghani, A. H., Pehlivanoglu, S., Alici, H., Tahtaci, H., & Uysal, S. (2025). Synthesis and characterization of schiff bases and their ag(i) complexes containing 2,5,6-trisubstituted imidazothiadiazole derivatives: molecular docking and in vitro cytotoxic effects against nonsmall lung cancer cell line. *Journal of Biochemical and Molecular Toxicology*, 39(2), e70142. <https://doi.org/10.1002/jbt.70142>
- Muttaqin, F. Z. (2019). Molecular docking and molecular dynamic studies of stilbene derivative compounds as sirtuin-3 (Sirt3) histone deacetylase inhibitor on melanoma skin cancer and their toxicities prediction. *Journal of Pharmacopolium*, 2(2). https://ejurnal.universitastbth.ac.id/index.php/P3M_JoP/article/view/489

- Naufa, F., Mutiah, R., Yen, Y., & Indrawijaya, A. (2022). Studi in silico potensi senyawa katekin teh hijau (*Camellia sinensis*) sebagai antivirus SARS CoV-2 terhadap spike glycoprotein (6LZG) dan main protease (5R7Y). *J. Food Pharm. Sci*, 10(1), 584–596. <https://doi.org/10.22146/jfps.3580>
- Pecci, F., Nakazawa, S., Ricciuti, B., Harada, G., Lee, J. K., Alessi, J. V., Barrichello, A., Vaz, V. R., Lamberti, G., & Di Federico, A. (2024). Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors. *Cancer Discovery*, 14(8), 1440–1456. 10.1158/2159-8290.CD-23-1217
- Pratama, A. B., Herowati, R., & Ansory, H. M. (2021). Studi docking molekuler senyawa dalam minyak atsiri pala (*Myristica fragrans* H.) dan senyawa turunan miristisin terhadap target terapi kanker kulit. *Majalah Farmaseutik*, 17(2), 233–242. <https://doi.org/10.22146/farmaseutik.v17i2.59297>
- Samec, M., Mazurakova, A., Lucansky, V., Koklesova, L., Pecova, R., Pec, M., Golubnitschaja, O., Al-Ishaq, R. K., Caprnda, M., & Gaspar, L. (2023). Flavonoids attenuate cancer metabolism by modulating lipid metabolism, amino acids, ketone bodies and redox state mediated by Nrf2. *European Journal of Pharmacology*, 949, 175655. <https://doi.org/10.1016/j.ejphar.2023.175655>
- Sari, I. W., Junaidin, J., & Pratiwi, D. (2020). Studi molecular docking senyawa flavonoid herba kumis kucing (*Orthosiphon Stamineus* B.) pada reseptor a-glukosidase sebagai antidiabetes tipe 2. *Jurnal Farmagazine*, 7(2), 54–60. <http://dx.doi.org/10.47653/farm.v7i2.194>
- Schrank, Z., Chhabra, G., Lin, L., Iderzorig, T., Osude, C., Khan, N., Kuckovic, A., Singh, S., Miller, R. J., & Puri, N. (2018). Current molecular-targeted therapies in NSCLC and their mechanism of resistance. *Cancers*, 10(7), 224. 10.3390/cancers10070224
- Sethi, A., Joshi, K., Sasikala, K., & Alvala, M. (2019). Molecular docking in modern drug discovery: principles and recent applications. *Drug Discovery and Development-New Advances*, 2, 1–21. 10.5772/intechopen.85991
- Sever, B., Otsuka, M., Fujita, M., & Ciftci, H. (2025). Design, synthesis, and anticancer evaluation of new small-molecule EGFR inhibitors targeting NSCLC and breast cancer. *International Journal of Molecular Sciences*, 26(15), 7065. <https://doi.org/10.3390/ijms26157065>
- Wang, B., Wang, Q., Yuan, R., Yang, S., Lu, M., Yuan, F., Dong, Z., Mo, M., Pan, Q., & Gao, H. (2023). Prenylated chromones and flavonoids isolated from the roots of *Flemingia macrophylla* and their anti-lung cancer activity. *Chinese Medicine*, 18(1), 153. <https://doi.org/10.1186/s13020-023-00860-3>

- Wati, W., PamudjiWidodoa, G., & Herowati, R. (2020). *Syzygium cumini*. *Jurnal Kimia Sains Dan Aplikasi* 23, 6, 189–195. <https://doi.org/10.14710/jksa.23.6.189-195>
- Zarev, Y., Foubert, K., de Almeida, V. L., Anthonissen, R., Elgorashi, E., Apers, S., Ionkova, I., Verschaeve, L., & Pieters, L. (2017). Antigenotoxic prenylated flavonoids from stem bark of *Erythrina latissima*. *Phytochemistry*, 141, 140–146. 10.1016/j.phytochem.2017.06.003
- Zhang, X., & Wu, C. (2022). *In silico*, *in vitro*, and *in vivo* evaluation of the developmental toxicity, estrogenic activity, and mutagenicity of four natural phenolic flavonoids at low exposure levels. *ACS Omega*, 7(6), 4757–4768. <https://doi.org/10.1021/acsomega.1c04239>

